Screener
CytomX Therapeutics CTMX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -476.2%-507pp | -181.9%-206pp | -29.4%-47.4pp | 20.5%+15.2pp | 30.6%+25.8pp | |
| Net margin | -435.2%-469pp | -166.4%-195pp | -22.8%-45.9pp | 24.7%— | 34%— | |
| Returns | ||||||
| Return on equity | -37.8%— | -34.3%— | —— | —— | —— | |
| Return on invested capital | -47.3%— | —— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.8× | 0.2×-0.9× | 0.6×-0.3× | 0.8×+0.1× | 0.8×+0.2× | |
| Liquidity | ||||||
| Current ratio | 9.4×+5.2× | 10.4×+8.7× | 3.1×+1.8× | 3.6×+2.6× | 4.2×+3.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×-0.3× | 0×— | 0.1×— | 0.1×— | |
| Per Share | ||||||
| Book value per share | $1.38+48.5% | $1.80+528% | $0.72+13,393% | $0.65+336% | $0.93+353% | |
| Valuation | ||||||
| Market capitalization | $753.93M+97.9% | $1.02B+1,895% | $721.79M+795% | $526.07M+471% | $337.14M+255% | |
| Price / sales | 41.2×+38.5× | 28.6×+28.2× | 9.5×+8.9× | 4.6×+3.9× | 2.4×+1.6× | |
| Price / book | 2.5×-0.7× | 3.2×+1.1× | 7.3×— | 4.9×— | 2.8×— |
FAQ
- Where do CytomX Therapeutics's ratios come from?
- Every ratio is computed from CytomX Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
